Latest news and articles about eli lilly from NEX English
Eli Lilly has announced that its new drug 'Foundio' has received approval from the US Food and Drug Administration, paving the way for strong competition in the oral obesity medication market. This development comes as companies strive to provide effective solutions to the global obesity crisis.
Insilico Medicine has announced a collaboration agreement with Eli Lilly worth <strong>$2.75 billion</strong> aimed at developing new drugs. This partnership comes at a time when the pharmaceutical industry is increasingly turning to modern technology for research and development.
The U.S. Food and Drug Administration (FDA) has approved the weight loss drug "Fondue," developed by Eli Lilly. This decision comes at a time when effective solutions to combat obesity, a global health crisis, are increasingly needed.
Novo Nordisk has achieved the best obesity drug launch this year with its medication Wegovy, surpassing 600,000 prescriptions. This move comes as Eli Lilly intensifies competition by introducing new pills to attract patients.
Insilico Medicine, listed in Hong Kong, has announced a strategic partnership with American company Eli Lilly to develop new drugs using artificial intelligence technologies. The deal could be worth up to $2.75 billion, with an initial payment of $115 million.